Zai Lab Announces Upcoming Presentations at November Conferences

SHANGHAI, China and SAN FRANCISCO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this November. Details of the conferences are as follows:

Goldman Sachs China Conference 2019
Presentation: Tuesday, November 5, 2019 at 3:15 p.m. CST
Presenter: Billy Cho, Chief Financial Officer
Location: Ritz Carlton, Shenzhen, China

Jefferies China Summit 2019
Presentation: Friday, November 15, 2019 at 8:30 a.m. CST
Presenter: Billy Cho, Chief Financial Officer
Location: JW Marriott, Hong Kong, China

BioCentury China Healthcare Summit 2019
Presentation: Tuesday, November 19, 2019 at 9:00 a.m. CST
Presenter: Tao Fu, President & Chief Operating Officer
Location: Jing An Shangri-La, Shanghai, China

Jefferies 2019 London Healthcare Conference
Presentation: Wednesday, November 20, 2019 at 1:20 p.m. GMT
Presenter: Billy Cho, Chief Financial Officer
Location: The Waldorf Hilton, London, UK

Goldman Sachs Asia Pacific Healthcare Forum 2019     
Presentation: Monday, November 25, 2019 at 9:00 a.m. CST
Presenter: Samantha Du, Founder & Chief Executive Officer
Location: Conrad, Hong Kong, China

A live webcast of the Jefferies 2019 London Healthcare Conference presentation will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai Lab
Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
[email protected]

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
[email protected] / [email protected]

Investors: Pete Rahmer
Endurance Advisors, on behalf of Zai Lab
415-515-9763
[email protected]

Zai Lab Limited

You May Also Be Interested In

• ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
• Start of Day Message
• Equinor ASA: Share buy-back – second tranche for 2026